Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F14%3A10283728" target="_blank" >RIV/00179906:_____/14:10283728 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11150/14:10283728
Výsledek na webu
<a href="http://www.dovepress.com/targeted-treatment-for-chronic-lymphocytic-leukemia-clinical-potential-peer-reviewed-article-PGPM" target="_blank" >http://www.dovepress.com/targeted-treatment-for-chronic-lymphocytic-leukemia-clinical-potential-peer-reviewed-article-PGPM</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2147/PGPM.S55501" target="_blank" >10.2147/PGPM.S55501</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab
Popis výsledku v původním jazyce
Introduction of targeted agents revolutionized the treatment of chronic lymphocytic leukemia (CLL) in the past decade. Addition of chimeric monoclonal anti-CD20 antibody rituximab to chemotherapy significantly improved efficacy including overall survival(OS) in untreated fit patients; humanized anti-CD52 antibody alemtuzumab and fully human anti-CD20 antibody ofatumumab lead to improvement in refractory disease. Novel small molecule inhibitors such as ibrutinib and idelalisib demonstrated excellent activity and were very recently licensed in relapsed/refractory CLL. Obinutuzumab (GA101) is the newest monoclonal antibody approved for the treatment of CLL. This novel, glycoengineered, type II humanized anti-CD20 antibody is characterized by enhanced antibody-dependent cellular cytotoxicity and direct induction of cell death compared to type I antibodies. Combination of obinutuzumab and chlorambucil yielded significantly better OS in comparison to chlorambucil monotherapy in untreated co
Název v anglickém jazyce
Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab
Popis výsledku anglicky
Introduction of targeted agents revolutionized the treatment of chronic lymphocytic leukemia (CLL) in the past decade. Addition of chimeric monoclonal anti-CD20 antibody rituximab to chemotherapy significantly improved efficacy including overall survival(OS) in untreated fit patients; humanized anti-CD52 antibody alemtuzumab and fully human anti-CD20 antibody ofatumumab lead to improvement in refractory disease. Novel small molecule inhibitors such as ibrutinib and idelalisib demonstrated excellent activity and were very recently licensed in relapsed/refractory CLL. Obinutuzumab (GA101) is the newest monoclonal antibody approved for the treatment of CLL. This novel, glycoengineered, type II humanized anti-CD20 antibody is characterized by enhanced antibody-dependent cellular cytotoxicity and direct induction of cell death compared to type I antibodies. Combination of obinutuzumab and chlorambucil yielded significantly better OS in comparison to chlorambucil monotherapy in untreated co
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
<a href="/cs/project/NT13412" target="_blank" >NT13412: Komplexní hodnocení vlivu mikroprostředí na klinický průběh chronické lymfocytární leukémie</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2014
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Pharmacogenomics and Personalized Medicine
ISSN
1178-7066
e-ISSN
—
Svazek periodika
8
Číslo periodika v rámci svazku
2014
Stát vydavatele periodika
GB - Spojené království Velké Británie a Severního Irska
Počet stran výsledku
7
Strana od-do
1-7
Kód UT WoS článku
—
EID výsledku v databázi Scopus
—